The current financial score of Arrowhead Pharmaceuticals Inc is 8.09. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 75.25M, representing a year-over-year increase of 171.02%, while its net profit experienced a year-over-year increase of 10.86%.
The current valuation score of Arrowhead Pharmaceuticals Inc is 9.61. Its current P/E ratio is -35.53, which is -239.31% below the recent high of 49.49 and -16756.05% above the recent low of -5988.52.
The current earnings forecast score of Arrowhead Pharmaceuticals Inc is 8.57. The average price target is 109.89, with a high of 126.00 and a low of 98.66.
The current price momentum score of Arrowhead Pharmaceuticals Inc is 2.97. Currently, the stock price is trading between the resistance level at 87.26 and the support level at 77.03, making it suitable for range-bound swing trading.
The current institutional shareholding score of Arrowhead Pharmaceuticals Inc is 7.00. The latest institutional shareholding proportion is 79.34%, representing a quarter-over-quarter decrease of 10.25%.
The current risk assessment score of Arrowhead Pharmaceuticals Inc is 5.79. The company's beta value is 1.29. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.